Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Better outcomes and fewer failures drive innovation in rheumatoid arthritis

This article was originally published in Scrip

Executive Summary

While market-leading anti-tumor necrosis factor (TNF) agents such as Humira (adalimumab; AbbVie/Eisai) and Enbrel (etanercept; Amgen/Pfizer/Takeda) have revolutionized the treatment of rheumatoid arthritis, there continues to be a significant unmet need for novel therapies that are associated with fewer treatment failures and inadequate responders. Recent Datamonitor Healthcare analysis of the early phase rheumatoid arthritis pipeline has identified the most commercially attractive opportunities in this therapy area, all still at a relatively early stage of investigation. "Recent innovation in the rheumatoid arthritis market is focused on demonstrating a superior clinical profile to the well-established anti-TNFs through biologics with novel mechanisms of action or novel oral small molecules," Datamonitor Healthcare analyst Christina Vasiliou told Scrip.

You may also be interested in...



UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer

Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.

Topics

Related Companies

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel